Recordati Ireland Limited

Carlo De Toma

Carlo Riva

Davide Graziani

Elena Poggesi

Patrizia Angelico

Amedeo Leonardi

Gianni Motta

Luciano Guarneri

Katia Dimitrova Karamfilova

Elena Poggessi

This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptors

The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

Spiroheterocyclic compounds as mGlu5 antagonists

Growing community of inventors

Milan, Italy

Carlo De Toma